NO305560B1 - Krystallinsk 3-(4-heksyloksy-1,2,5-tiadiazol-3-yl)-1,2,5,6-tetrahydro-1-metylpyridin-(+)-L-hydrogentartrat, farmas°ytiske preparater som omfatter forbindelsen, samt anvendelse av forbindelsen til fremstilling av et medikament - Google Patents

Krystallinsk 3-(4-heksyloksy-1,2,5-tiadiazol-3-yl)-1,2,5,6-tetrahydro-1-metylpyridin-(+)-L-hydrogentartrat, farmas°ytiske preparater som omfatter forbindelsen, samt anvendelse av forbindelsen til fremstilling av et medikament

Info

Publication number
NO305560B1
NO305560B1 NO954892A NO954892A NO305560B1 NO 305560 B1 NO305560 B1 NO 305560B1 NO 954892 A NO954892 A NO 954892A NO 954892 A NO954892 A NO 954892A NO 305560 B1 NO305560 B1 NO 305560B1
Authority
NO
Norway
Prior art keywords
compound
thiadiazol
methylpyridine
hexyloxy
tetrahydro
Prior art date
Application number
NO954892A
Other languages
English (en)
Other versions
NO954892L (no
NO954892D0 (no
Inventor
Linda Marie Osborne
Lisa Ann Shipley
Svend Treppendahl
Torben Guldager Petersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO954892L publication Critical patent/NO954892L/no
Publication of NO954892D0 publication Critical patent/NO954892D0/no
Publication of NO305560B1 publication Critical patent/NO305560B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO954892A 1993-06-04 1995-12-01 Krystallinsk 3-(4-heksyloksy-1,2,5-tiadiazol-3-yl)-1,2,5,6-tetrahydro-1-metylpyridin-(+)-L-hydrogentartrat, farmas°ytiske preparater som omfatter forbindelsen, samt anvendelse av forbindelsen til fremstilling av et medikament NO305560B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7257293A 1993-06-04 1993-06-04
PCT/DK1994/000205 WO1994029303A1 (en) 1993-06-04 1994-05-26 Heterocyclic chemistry

Publications (3)

Publication Number Publication Date
NO954892L NO954892L (no) 1995-12-01
NO954892D0 NO954892D0 (no) 1995-12-01
NO305560B1 true NO305560B1 (no) 1999-06-21

Family

ID=22108479

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954892A NO305560B1 (no) 1993-06-04 1995-12-01 Krystallinsk 3-(4-heksyloksy-1,2,5-tiadiazol-3-yl)-1,2,5,6-tetrahydro-1-metylpyridin-(+)-L-hydrogentartrat, farmas°ytiske preparater som omfatter forbindelsen, samt anvendelse av forbindelsen til fremstilling av et medikament

Country Status (22)

Country Link
US (1) US5834495A (no)
EP (1) EP0703915B1 (no)
JP (1) JP3190679B2 (no)
KR (1) KR100339115B1 (no)
CN (1) CN1064681C (no)
AT (1) ATE196631T1 (no)
AU (1) AU698673B2 (no)
CA (1) CA2164296C (no)
CZ (1) CZ290550B6 (no)
DE (1) DE69426021T2 (no)
DK (1) DK0703915T3 (no)
ES (1) ES2152315T3 (no)
FI (1) FI955829A (no)
GR (1) GR3035033T3 (no)
HU (1) HUT75038A (no)
IL (1) IL109866A (no)
NO (1) NO305560B1 (no)
NZ (2) NZ267062A (no)
PT (1) PT703915E (no)
SK (1) SK281980B6 (no)
WO (1) WO1994029303A1 (no)
ZA (1) ZA943904B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043258A (en) * 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
EP0821956A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating disruptive behavior disorders
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
EP0821954A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating mental retardation
US6090829A (en) * 1996-08-01 2000-07-18 Eli Lilly And Company Method for treating excessive aggression
US6034108A (en) * 1997-07-28 2000-03-07 Eli Lilly And Company Method for treating mental retardation
US10596139B2 (en) 2015-03-06 2020-03-24 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system muscarinic agonist combination
CN115974863A (zh) * 2021-10-14 2023-04-18 南京迈诺威医药科技有限公司 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5264444A (en) * 1989-02-22 1993-11-23 Novo Nordisk A/S Piperidine compounds and use
US5260311A (en) * 1989-02-22 1993-11-09 Novo Nordisk A/S Piperidine compounds and their use

Also Published As

Publication number Publication date
IL109866A (en) 2000-06-01
DK0703915T3 (da) 2001-01-22
AU6924294A (en) 1995-01-03
PT703915E (pt) 2001-03-30
DE69426021T2 (de) 2001-05-17
CN1128999A (zh) 1996-08-14
NZ336733A (en) 2001-02-23
JPH08511008A (ja) 1996-11-19
CZ321095A3 (en) 1996-09-11
US5834495A (en) 1998-11-10
CN1064681C (zh) 2001-04-18
NZ267062A (en) 1999-09-29
JP3190679B2 (ja) 2001-07-23
NO954892L (no) 1995-12-01
DE69426021D1 (de) 2000-11-02
HU9503453D0 (en) 1996-01-29
FI955829A0 (fi) 1995-12-04
EP0703915B1 (en) 2000-09-27
EP0703915A1 (en) 1996-04-03
CA2164296A1 (en) 1994-12-22
ZA943904B (en) 1995-12-04
SK281980B6 (sk) 2001-09-11
WO1994029303A1 (en) 1994-12-22
KR100339115B1 (ko) 2002-11-07
ATE196631T1 (de) 2000-10-15
HUT75038A (en) 1997-03-28
GR3035033T3 (en) 2001-03-30
SK152095A3 (en) 1996-10-02
FI955829A (fi) 1995-12-04
CZ290550B6 (cs) 2002-08-14
AU698673B2 (en) 1998-11-05
NO954892D0 (no) 1995-12-01
ES2152315T3 (es) 2001-02-01
CA2164296C (en) 2007-01-23
KR960702835A (ko) 1996-05-23
IL109866A0 (en) 1994-10-07

Similar Documents

Publication Publication Date Title
NO308107B1 (no) Ikke-solvatert krystallinsk forbindelse, farmasøytisk formulering inneholdende denne samt anvendelse av forbindelsen for fremstilling av et farmasøytisk middel
NO895086L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser.
NO904694D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
NO901684L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater.
NO902411D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-hydroksy-n-propylaminer.
NO880182D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1, 2-dihydro-3h-indazol-3h-indazol-3-on-derivater.
MY123193A (en) Novel 2-(iminomethyl)amino-phenyl derivatives,preparation,application as medicines and compositions containing same
NO305903B1 (no) Benzonitriler og benzofluorider, legemidler bestående av forbindelsene, farmasöytiske preparater inneholdende forbindelsene, samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
MY124146A (en) Novel 2-(iminomethyl) amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same
NO302368B1 (no) Kinoksalinforbindelser, farmasöytiske preparater som inneholder slike, og anvendelse av forbindelsene for fremstilling av preparatene
NO303578B1 (no) Anvendelse av 2,3-trans-disubstituerte tropanforbindelser for fremstilling av medikamenter, samt slike forbindelser og farmas°ytiske preparater som omfatter dem
NO890155D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive indolpiperidin-forbindelser.
NO305560B1 (no) Krystallinsk 3-(4-heksyloksy-1,2,5-tiadiazol-3-yl)-1,2,5,6-tetrahydro-1-metylpyridin-(+)-L-hydrogentartrat, farmas°ytiske preparater som omfatter forbindelsen, samt anvendelse av forbindelsen til fremstilling av et medikament
NO165104C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 1, 1-disubstituerte cyklopropanderivater.
NO167861C (no) Analogifremgangsmaate for fremstilling av en ny, terapeutisk aktiv indolokinolinforbindelse.
NO895220D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzenderivater.
NO305836B1 (no) Oksazolidin-2-on-forbindelser, farmas°ytiske preparater som inneholder minst Ún slik forbindelse, samt anvendelse av forbindelsene til fremstilling av legemidler
NO903347L (no) 14,17alfa-ethano- og ethanooestratriener, fremgangsmaate forfremstilling av disse forbindelser, saavel som anvendelse av dem for fremstilling av legemidler.
NO883986L (no) Fremgangsmaate for fremstilling av n-(substituert alkyliden)-1,2,3,4-tetrahydro-9-akridinaminer og anvendelse derav som medikamenter.
DK11089D0 (da) 2,5-diazabicyclooe2.2.1aaheptan-forbindelser, deres anvendelse til fremstilling af antiarytmi-laegemidler, farmaceutiske praeparater indeholdende forbindelserne samt forbindelse til anvendelse som udgangsmateriale ved deres fremstilling
ATE169819T1 (de) (-)-metrifonat enthaltendes arzneimittel
NO900972L (no) Fremgangsmaate for fremstilling av terapeutisk aktive naftalen-derivater.
ES2062940A1 (es) Agente gastrocinetico, proceso para su preparacion y composiciones farmaceuticas que lo contengan.
NO882279D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive endo-bicyklo (2,2,1) heptyl-adenosin-derivater.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN NOVEMBER 2003